Practically, FKBP5 is the leading pharmacodynamic candidate for monitoring HP engagement (adjacent/peripheral compartments), CLDN4 informs tumor epithelial remodeling, which should serve as a complementary context readout (e.g., perioperative risk stratification or supportive interpretation of exposure), ideally confirmed at the protein/serum level and interpreted alongside inflammatory markers and clinical covariates. The gene discussed is CLDN4; the disease is neoplasm.